Thomas F.

Eleva is opening the realm of unprecedented therapies with the help of an inconspicuous but incredibly efficient tool: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they virtually invite easy, stable engineering and reliable output. We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

eleva GmbH
Hans-Bunte-Str. 19
0761 470 99 0
0761 470 99 190

Der BioValley Deutschland e.V. bietet allen relevanten Kräften aus Wissenschaft und Wirtschaft, die die Entwicklung der Biotechnologie in unserer Region unterstützen und fördern wollen, eine gemeinsame Plattform.